Biweekly regimen of cisplatin, gemcitabine and vinorelbine for advanced non-small-cell lung cancer

被引:2
作者
de Carpeño, JC
Barón, MG
Aguiar, J
Chacón, JI
Feliu, J
García, MJ
Madroñal, C
Colmenarejo, A
Sánchez, JJ
Ordóñez, A
机构
[1] Dept Med Oncol, Madrid 28046, Spain
[2] Hosp Dr Negrin, Dept Med Oncol, Las Palmas Gran Canaria, Spain
[3] Hosp Virgen Salud, Dept Med Oncol, Toledo, Spain
[4] Hosp Nuestra Senora de Alarcos, Dept Med Oncol, Ciudad Real, Spain
[5] Clin Corachan, Dept Med Oncol, Barcelona, Spain
[6] Hosp Cent Def Gomez Ulla, Dept Med Oncol, Madrid, Spain
[7] Autonomous Univ Madrid, Dept Prevent Med, E-28049 Madrid, Spain
关键词
non-small-cell lung carcinoma; gemcitabine; cisplatin; chemotherapy; vinorelbine; triplets;
D O I
10.1007/s00280-005-0143-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Improving chemotherapeutic efficacy in non-small cell lung cancer (NSCLC) will require the development of new strategies to better use currently available agents. To assess the efficacy and safety of a biweekly regimen of cisplatin, gemcitabine and vinorelbine for advanced non-small-cell lung cancer. Methods: Patients with selected stage IIIb (pleural effusion)/stage IV NSCLC, performance status of 0-2 and normal organ function were eligible. Treatment consisted of cisplatin 100 mg/m(2) on day 1 plus gemcitabine, 1,000 mg/m(2) and vinorelbine 25 mg/m(2) on days 1 and 15 every 28 days. Results: Of the 40 patients enrolled and assessable for response, there were five (12.5%) with confirmed complete response and 14 (35%) with a confirmed partial response for an overall response rate of 47.5%. Nine patients had stable disease while 12 (30%) progressed. Median progression-free survival and overall survival for all patients were 6.3 and 11.1 months, respectively. Toxicity was principally hematologic, with grade 3-4 neutropenia in 30%, and grade 3-4 nausea/vomiting in 22.5%. There were no treatment-related deaths. Conclusions: The biweekly regimen of cisplatin, gemcitabine and vinorelbine is associated with a high rate of response, lesser toxicity than other three-drug regimens and no benefit of survival. Therefore, the regimen under study may be an appealing alternative when considering other treatment modalities for advanced lung cancer, such as neoadjuvant therapy.
引用
收藏
页码:266 / 271
页数:6
相关论文
共 28 条
  • [1] Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer:: A Spanish lung cancer group phase III randomized trial
    Alberola, V
    Camps, C
    Provencio, M
    Isla, D
    Rosell, R
    Vadell, C
    Bover, I
    Ruiz-Casado, A
    Azagra, P
    Jiménez, U
    González-Larriba, JL
    Diz, P
    Cardenal, F
    Artal, A
    Carrato, A
    Morales, S
    Sánchez, JJ
    de las Peñas, R
    Felip, E
    López-Vivanco, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) : 3207 - 3213
  • [2] [Anonymous], 1989, Analysis of binary data
  • [3] BARON MG, 1998, P AN M AM SOC CLIN, V17, pA482
  • [4] Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an eastern cooperative oncology group trial
    Bonomi, P
    Kim, KM
    Fairclough, D
    Cella, D
    Kugler, J
    Rowinsky, E
    Jiroutek, M
    Johnson, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) : 623 - 631
  • [5] Biweekly vinorelbine and gemcitabine:: a phase I dose-finding study in patients with advanced solid tumors
    Castellano, D
    Hitt, R
    Ciruelos, E
    Cortés-Funes, H
    Colomer, R
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (05) : 783 - 787
  • [6] Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: A phase II randomized study of the Southern Italy Cooperative Oncology Group
    Comella, P
    Frasci, G
    Panza, N
    Manzione, L
    Lorusso, V
    Di Rienzo, G
    Cioffi, R
    De Cataldis, G
    Maiorino, L
    Bilancia, D
    Nicolella, G
    Natale, M
    Carpagnano, F
    Pacilio, C
    De Lena, M
    Bianco, A
    Comella, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) : 1526 - 1534
  • [7] Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: Interim analysis of a phase III trial of the southern Italy Cooperative Oncology Group
    Comella, P
    Frasci, G
    Panza, N
    Manzione, L
    De Cataldis, G
    Cioffi, R
    Maiorino, L
    Micillo, E
    Lorusso, V
    Di Rienzo, G
    Filippelli, G
    Lamberti, A
    Natale, M
    Bilancia, D
    Nicolella, G
    Di Nota, A
    Comella, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (07) : 1451 - 1457
  • [8] DORTA J, 1998, P AN M AM SOC CLIN, V17, pA482
  • [9] Phase I/II study of gemcitabine and vinorelbine plus cisplatin in non-small cell lung cancer
    Esteban, E
    Fra, J
    Sala, M
    Carrasco, J
    Corral, N
    Vieitez, JM
    Estrada, E
    Palacio, I
    Buesa, JM
    Lacave, AJ
    [J]. INVESTIGATIONAL NEW DRUGS, 2002, 20 (03) : 317 - 326
  • [10] Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine.: A phase II study
    Feliu, J
    Martín, G
    Lizón, J
    Chacón, JI
    Dorta, J
    de Castro, J
    Rodríguez, A
    Heras, BS
    Torrego, JC
    Espinosa, E
    Barón, MG
    [J]. ANNALS OF ONCOLOGY, 2001, 12 (10) : 1369 - 1374